An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study

Protocol No

ORYZON-CL04-ORY-1001

Phase

I

Summary

This project is being done to learn about the safety, tolerability and efficacy [how well a drug works] of iadademstat in combination with gilteritinib for the treatment of R/R AML with FLT3 mut+.

Description

Study of iadademstat and gilteritinib in patients with R/R AML with FMS-like T/K mutation

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL